ABSTRACT
BACKGROUND Recent trials show a lack of benefit of routine aspirin use for primary prevention. We assessed recent trends in aspirin use for both primary and secondary prevention in the United States population.
METHODS We used National Health Interview Survey (NHIS) data from 2015-2023 and reported the annual weighted proportion of aspirin use among participants ≥40 years without a self-reported history of angina, coronary heart disease, myocardial infarction, or stroke (primary prevention cohort) and those with (secondary prevention cohort), overall and by subgroups. Statistical comparisons were made only between 2019 and 2023 due to an NHIS study redesign in 2019.
RESULTS From 2019 to 2023 overall aspirin use for primary prevention decreased from 20.6% to 15.7%. It declined in all subgroups, including among individuals ≥70 years from 38.7% to 30.7%, and those age <60 years but with ≥3 CVD risk factors (29.1% to 19.7%). Overall aspirin use for secondary prevention also declined, but to a lesser extent from 65.7% to 61.9%. (all P <0.001)
CONCLUSION In response to recent data there has been a significant reduction in aspirin use for primary prevention, appropriately among older participants, but also among younger participants with multiple cardiovascular risk factors. There was also a minor decrease in its use for secondary prevention which warrants further study.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Murugiah received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K08HL157727).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://www.cdc.gov/nchs/nhis/data-questionnaires-documentation.htm
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Added 2023 data. There was also an error in the prior version of the manuscript in handling missing that I have corrected.
Data Availability
All data produced are available online at https://www.cdc.gov/nchs/nhis/data-questionnaires-documentation.htm
https://www.cdc.gov/nchs/nhis/data-questionnaires-documentation.htm
